Dr. Elizabeth Plimack, MD, MS, FASCO, is a Professor of Medical Oncology and the Deputy Director of Fox Chase Cancer Center. A recognized leader in the treatment of genitourinary malignancies, Dr. Plimack’s work primarily focuses on bladder and kidney cancers. At Fox Chase Cancer Center, Dr. Plimack and her team have pioneered an innovative approach to bladder preservation in patients with muscle-invasive bladder cancer (MIBC). Through clinical trials like RETAIN-1 and RETAIN-2, they are challenging traditional treatment paradigms by exploring systemic therapy-based strategies as alternatives to radical ...
Urothelial Carcinoma
Advertisement
Latest News
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Advertisement
Latest News
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.